Genetics of hereditary hemochromatosis: A clinical perspective

Expert Review of Endocrinology and Metabolism

Volumn 4, Issue 3, 2009, Pages 225-239

  Gan, Eng K ^a   Trinder, Debbie ^a   Ayonrinde, Oyekoya T ^a   Olynyk, John K ^a  

^a FREMANTLE HOSPITAL   (Australia)

Author keywords

C282Y mutation; Clinical penetrance; Ferritin; HFE hermochromatosis; Iron overload phenotype

Indexed keywords

ASPARTIC ACID; BONE MORPHOGENETIC PROTEIN; CD71 ANTIGEN; COLLAGEN TYPE 4; CYSTEINE; FERRITIN; FERROPORTIN; GLUTATHIONE TRANSFERASE P1; GROWTH DIFFERENTIATION FACTOR 15; HAPTOGLOBIN; HEMOJUVELIN; HEPCIDIN; HFE PROTEIN; HISTIDINE; HYALURONIC ACID; IMMUNOGLOBULIN; IRON BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NONHEME IRON PROTEIN; PLASMA PROTEIN; TRANSFERRIN RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TYROSINE;

ALCOHOL CONSUMPTION; CITRUS FRUIT; ENVIRONMENTAL FACTOR; FATTY LIVER; FERRITIN BLOOD LEVEL; FIBROGENESIS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEMOCHROMATOSIS; HORMONE PROTEIN COMPLEX; HUMAN; IRON ABSORPTION; IRON INTAKE; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FIBROSIS; MASS SCREENING; NONHUMAN; OXIDATIVE STRESS; PENETRANCE; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; VIRUS HEPATITIS;

EID: 70149087337     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.09.9     Document Type: Review

References (136)

1. Feder JN, Gnirke A, Thomas W et al. A novel MHC class 1-like gene is mutated in patients with hereditary hemochromatosis. Nat. Genet. 13, 399-408 (1996).
2. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med. 341, 718-724 (1999).
3. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative hemochromatosis mutations. J. Med. Genet. 34, 275-278 (1997).
4. Rossi E, Henderson S, Chin CYB et al. Genotyping as a diagnostic aid in genetic hemochromatosis. J. Gastro. Hepatol. 14, 427-430(1999).
5. Andrews NC. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999).
6. Chua ACG, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci. 44, 413-459 (2007).
7. Adams PC, Barton JC. Haemochromatosis. Lancet 370, 1855-1860 (2007).
8. McKie AT, Barrow D, Latunde-Dada GO et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science 291, 1755-1759 (2001).
9. McKie AT, Marciani P, Rolfs A et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell 5, 299-309 (2000).
10. Vulpe CD, Kuo Y-M, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet. 21, 195-199 (1999).
11. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72, 19-28 (1993).
12. Chua ACG, Morgan EH, Herbison CE et al. Iron uptake from plasma transferrin in a transferrin receptor 2 mutant mouse model of haemochromatosis type 3. Am. J. Hematol. 82, 531 (2007).
13. Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem. 264, 4417-4422 (1989).
14. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23, 185-192 (2000).
15. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis. 29, 327-335 (2002).
16. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093 (2004).
17. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 48(3), 991-1001 (2008).
18. Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 110, 1037-1044 (2002).
19. Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine (Baltimore) 34, 381-430 (1955).
20. Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol. Dis. 330, 288-297 (2003).
21. Olynyk JK. Hereditary hemochromatosis: diagnosis and management in the gene era. Liver 19, 73-80 (1999).
22. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology 122, 646-651 (2002).
23. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJH. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet. Test. 4, 151-161 (2000).
24. Camaschella C. Juvenile hemochromatosis. Baillieres Clin. Gastroenterol. 12, 227-235 (1998).
25. Pietrangelo A. Non-HFE hemochromatosis. Semin. Liv. Dis. 450-460 (2005).
26. Papanikolaou G, Samuels ME, Ludwig EH et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet. 36, 77-82 (2004).
27. Rivard SR, Lanzara C, Grimard D et al. Juvenile hemochromatosis locus maps to chromosome 1q in a French Canadian population. Eur. J. Hum. Genet. 11, 585-589 (2003).
28. Lanzara SP, Roetto A, Caraio F et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood 103(11), 4317-4321 (2004).
29. Camaschella C, Roetto A, Calà A et al. The gene TFR2 is mutated in a new type of hemochromatosis mapping to 7q22. Nat. Genet. 25, 14-15 (2000).
30. De Gobbi M, Barilaro MR, Garozzo G, Sbaiz L, Alberti F, Camaschella C. TFR2 Y250X mutation in Italy. Br. J. Haematol. 114, 243-244 (2001).
31. Roetto A, Totaro A, Piperno A et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 97, 2555-2560 (2001).
32. Girelli D, Bozzini C, Roetto A et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 122, 1295-1302 (2002).
33. Koyama C, Wakusawa S, Hayashi H et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica 90, 302-307 (2005).
34. Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br. J. Haematol. 125, 674-678 (2004).
35. Mattman A, Huntsman D, Lockitch G et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood 100, 1075-1077 (2002).
36. Montosi G, Donovan A, Totaro A et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin ( SLC11A3) gene. J. Clin. Invest. 108, 619-623 (2001).
37. Njajou OT, Vaessen N, Joosse M et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet. 28, 213-214 (2001).
38. Rivers CA, Barton JC, Gordeuk VR et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol. Dis. 38,247-252 (2007).
39. Arden KE, Wallace DF, Dixon JL et al. A novel mutation in ferroportin 1 is associated with hemochromatosis in a Solomon Islands patient. Gut 52, 1215-1217 (2003).
40. Bach V, Remacha A, Altes A, Barcelo MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel ferroportin 1 mutations in Spain. Blood Cells Mol. Dis. 36,41-45 (2006).
41. Gordeuk VR, Caleffi A, Corradini E et al. Iron overload in Africans and African - Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol. Dis. 31, 299-304 (2003).
42. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood 102, 1904-1910 (2003).
43. Jouanolle A-M, Douabin-Gicquel V, Halimi C et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J. Hepatol. 39, 286-289 (2003).
44. De Domenico I, Ward DM, Nemeth E et al. The molecular basis of ferroportin-linked hemochromatosis. Proc. Natl Acad. Sci. USA 102, 8955-8960 (2005).
45. Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood 106, 1092-1097 (2005).
46. Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood 105, 4096-4102 (2005).
47. Chua ACG, Herbison CE, Drake SF et al. The role of HFE in transferrin-bound iron uptake by hepatocytes Hepatology 47(5), 1737-1744 (2008).
48. Siah CW, Trinder D, Olynyk JK. Iron overload. Clin. Chim. Acta 358, 24-36 (2005).
49. Gitlin JD. Aceruloplasminemia. Pediatr. Res. 44, 271-276 (1998).
50. Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am. J. Hum. Genet. 53, 201-213 (1993).
51. Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin. Liver Dis. 243-250 (2007).
52. Adams PC, Reboussin DM, Barton JC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med. 352, 1769-1778 (2005).
53. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet 359, 211-218 (2002).
54. Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood 103, 2914-2919 (2004).
55. Delatycki MB, Allen KJ, Nisselle AE et al. Use of community genetic screening to prevent HFE- associated hereditary hemochromatosis. Lancet 366, 314-316 (2005).
56. Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin. Proc. 79(3), 309-313 (2004).
57. Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin. Gastroenterol. Hepatol. 1(5), 388-391 (2003).
58. Powell LW, Dixon JL, Ramm GA et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Int. Med. 166, 294-301 (2006).
59. Gurrin LC, Osborne NJ, Constantine CC et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology 135(6), 1945-1952 (2008).
60. Barton JC, McDonnell SM, Adams PC et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann. Intern. Med. 129, 932-939 (1998).
61. Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358(3), 221-230 (2008).
62. Barton JC, Wiener HW, Acton RT, Go RC. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol. Dis. 34, 38-47 (2005).
63. + T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects. Blood Cells Mol. Dis. 37(1), 33-39 (2006).
64. Lim EM, Rossi E, De Boer WB, Reed WD, Jeffrey GP. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int. 24, 631-636 (2004).
65. Gurrin LC, Bertalli, Dalton GW et al. HFE-compound heterozygotes are at low risk of hemochromatosis-related morbidity (In Press) (2009).
66. Walsh A, Dixon JL, Ramm GA et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin. Gastroenterol. Hepatol. 114(5), 1003-1008 (1998).
67. Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. Crit. Rev. Clin. Lab. Sci. 45(5), 451-484 (2008).
68. McLaren CE, McLachlan GJ, Halliday JW et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology 114, 543-549 (1998).
69. Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology 120, 718-725 (2001).
70. Bomford A. Genetics of hemochromatosis. Lancet 360, 1673-1681 (2002).
71. Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann. Intern. Med. 145, 209-223 (2006).
72. Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferretin levels: a more effective approach. Blood 111, 3373-3376 (2008).
73. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am. J. Gastroenterol. 100, 837-841 (2005).
74. Powell LW, Dixon JL, Ramm GA et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Intern. Med. 166, 294-301 (2006).
75. Adams PC, Reboussin DM, Leiendecker-Foster C et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin. Chem. 51, 1048-1052 (2005).
76. Olynyk JK, Gan E, Tan T. Predicting iron overload in hyperferretinemia. Clin. Gastrol. Hepatol. 7(3), 359-362 (2009).
77. Vartsky D, Ellis KJ, Hull DM, Cohn SH. Nuclear resonant scattering of γ rays - a new technique for in vivo measurement of body iron stores. Phys. Med. Biol. 24, 689-701 (1979).
78. Leung AW, Steiner RE, Young IR. NMR imaging of the liver in 2 cases of iron overload. J. Comput. Assist. Tomogr. 8, 446-449 (1984).
79. Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 101, 15-19 (2003).
80. Adams PC. Review article: the modern diagnosis and management of haemochromatosis. Aliment. Pharmacol. Ther. 23, 1681-1691 (2006).
81. Alustiza JM, Artetxe J, Castiella A et al. MR quantification of hepatic iron concentration. Radiology 230, 479-484 (2004).
82. St Pierre TG, Clark PR, Chua-Anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105, 855-861 (2005).
83. Gandon Y, Olivie D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet 363, 357-362 (2004).
84. Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 115, 929-936 (1998).
85. Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand. J. Gastroenterol. 36, 1108-1115 (2001).
86. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann. Intern. Med. 130, 953-962 (1999).
87. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am. J. Gastroenterol. 95, 1788-1793 (2000).
88. Tavill AS. Diagnosis and management of hemochromatosis. Hepatology 33, 1321-1328 (2001).
89. Crawford DH, Murphy DL, Ramm LE et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis Hepatology 49(2), 418-425 (2009).
90. Burke W, Thomson E, Khoury MJ et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA 280, 172-178 (1998).
91. Alper JS, Geller LN, Barash CI, Billings PR, Laden V, Natowicz MR. Genetic discrimination and screening for hemochromatosis. J. Public Health Policy 15, 345-358 (1994).
92. Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families and population. Curr. Gastroenterol. Rep. 6, 44-51 (2004).
93. Smith PM, Godfrey BE, Williams R. Iron absorption in idiopathic haemochromatosis and its measurement using a whole-body counter. Clin. Sci. 37(2), 519-531 (1969).
94. Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood 74(6), 2187-2193 (1989).
95. McCune CA, Ravine D, Carter K et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut 55(4), 554-562 (2006).
96. Milward EA, Baines SK, Knuiman MW et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin. Proc. 83(5), 543-549 (2008).
97. Cade JE, Moreton JA, O'Hara B et al. Diet and genetic factors associated with iron status in middle-aged women. Am. J. Clin. Nutr. 82(4), 813-820 (2005).
98. Van der A DL, Peeters PH, Grobbee DE, Roest M, Voorbij HA, van der Schouw YT. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr. Metab. Cardiovasc. Dis. 16(1), 60-68 (2006).
99. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6(1), 24-29 (1986).
100. Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. The effect of haemochromatosis genotype and life-style factors on iron and red cell indices in a community population. Clin. Chem. 47, 202-208 (2001).
101. Moirand R, Lescoat G, Delamaire D et al. Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin. Exp. Res. 15(6), 963-969 (1991).
102. Scotet V, Merour MC, Mercier AY et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am. J. Epidemiol. 158(2), 129-134 (2003).
103. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122(2), 281-289 (2002).
104. Bridle K, Cheung TK, Murphy T et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin. Exp. Res. 30(1), 106-112 (2006).
105. Harrison-Findik DD, Schafer D, Klein E et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem. 281, 22974-22982 (2006).
106. Whitfield JB, Cullen LM, Jazwinska EC et al. Effects of HFE C2S2Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am. J. Hum. Genet. 66(4), 1246-1258 (2000).
107. Merryweather-Clarke AT, Cadet E, Bomford A et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum. Mol. Genet. 12(17), 2241-2247 (2003).
108. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 103(7), 2835-2840 (2004).
109. Le Gac G, Scotet V, Ka C et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum. Mol. Genet. 13(17), 1913-1918 (2004).
110. Piperno A, Mariani R, Arosio C et al. Haemochromatosis in patients with β-thalassaemia trait. Br. J. Haematol. 111(3), 908-914 (2000).
111. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13(9), 1096-1101 (2007).
112. Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am. J. Hum. Genet. 81(4), 799-807 (2007).
113. Lee PL, Gelbart T, West C, Halloran C, Felitti V, Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol. Dis. 27(5), 783-802 (2001).
114. Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol. Dis. 29(3), 471-487 (2002).
115. Benyamin B, McRae AF, Zhu G et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am. J. Hum. Genet. 84(1), 60-65 (2009).
116. Van Vlierberghe H, Langlois M, Delanghe J et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J. Hepatol. 35(6), 707-711 (2001).
117. Piperno A, Arosio C, Fargion S et al. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology 24(1), 43-46 (1996).
118. Pratiwi R, Fletcher LM, Pyper WR et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J. Hepatol. 31(1), 39-46 (1999).
119. Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology 23(4), 724-727 (1996).
120. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 124(2), 318-326 (2003).
121. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J. Hepatol. 36(5), 687-691 (2002).
122. Powell EE, Ali A, Clouston AD et al. Steacosis is a cofactor in liver injury in hemochromatosis. Gastroenterology 129(6), 1937-1943 (2005).
123. Valenti L, Fracanzani AL, Dongiovanni P et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case - control study. Am. J. Gastroenterol. 102(6), 1251-1258 (2007).
124. Di Martino V, Lebray P, Myers RP et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 40(6), 1426-1433 (2004).
125. Loréal O, Deugnier Y, Moirand R et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J. Hepatol. 16(1-2) 122-127 (1992).
126. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int. 23(1), 63-69 (2003).
127. Osterreicher CH, Datz C, Stickel F et al. TGF-β1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine 31(2), 142-148 (2005).
128. Fargion S, Valenti L, Dongiovanni P et al. Tumor necrosis factor α promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 97(12), 3707-3712 (2001).
129. Distante S, Elmberg M, Foss Haug KB et al. Tumour necrosis factor α and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis. Scand. J. Gastroenterol. 38(8), 871-877 (2003).
130. Beutler E, Gelbart T. Tumor necrosis factor α promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A(C282Y) hereditary hemochromatosis mutation. Letter. Blood 100(6), 2268-2269 (2002).
131. Marra F, DeFranco R, Grappone C et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 152(2), 423-430 (1998).
132. Mühlbauer M, Bosserhoff AK, Hartmann A et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 125(4), 1085-1093 (2003).
133. Stickel F, Osterreicher CH, Datz C et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch. Intern. Med. 165(16), 1835-1840 (2005).
134. Osterreicher CH, Datz C, Stickel F et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J. Hepatol. 42(6), 914-919 (2005).
135. Valenti L, Conte D, Piperno A et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J. Med. Genet. 41, 946-950 (2004).
136. Bulaj ZJ, Ajioka RS, Phillips JD et al. Disease-related conditions in relatives of patients with hemochromatosis. N. Engl. J. Med. 343(21), 1529-1535 (2000).